GlassScriptPhysician profile
Lane M Frey
NPI 1932337052
$201,859.22
in general payments reported to CMS, 2019-2025
40 companies · $29K in 2025
The $29K reported for 2025 was more than what 94% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $37K · 2020: $44K · 2021: $23K · 2022: $49K · 2023: $12K · 2024: $6,773 · 2025: $29K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $42K · Food and Beverage: $3,548 · Travel and Lodging: $2,190 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $41,895.12 |
| Food and Beverage | $3,548.38 |
| Travel and Lodging | $2,190.05 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $165,320.51 | 2019-2025 | Ozempic, Rybelsus, Saxenda |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24,193.88 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $8,387.89 | 2019-2025 | Mounjaro, Jardiance, Humulin |
| Astrazeneca Pharmaceuticals LP | $445.11 | 2019-2023 | Farxiga |
| Sanofi-Aventis U.S. LLC | $345.54 | 2019-2025 | |
| Abbott Laboratories | $342.13 | 2019-2025 | Freestyle Libre 3 |
| Amgen INC. | $338.91 | 2019-2025 | Evenity, Prolia, Tepezza |
| Dexcom, INC. | $234.29 | 2019-2024 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $225.00 | 2022-2025 | Gvoke Hypopen, Recorlev |
| Corcept Therapeutics | $169.44 | 2020-2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $154.60 | 2022-2025 | |
| Abbvie INC. | $153.28 | 2021-2025 | |
| Ibsa Pharma INC. | $130.52 | 2020-2025 | Tirosint, Licart, Tirosint |
| Antares Pharma, INC. | $125.76 | 2022-2025 | Xyosted, Tlando, Nocdurna |
| Tandem Diabetes Care, INC. | $113.29 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $106.34 | 2019-2025 | Omnipod |
| Beta Bionics, INC. | $106.23 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Medtronic, INC. | $101.47 | 2021-2025 | Minimed 780g |
| Tolmar, INC. | $86.36 | 2024-2025 | Jatenzo |
| Amneal Pharmaceuticals LLC | $83.69 | 2022-2025 | Unithroid |
| Merck Sharp & Dohme LLC | $79.32 | 2019-2023 | Steglatro |
| Novartis Pharmaceuticals Corporation | $59.31 | 2024-2025 | |
| Amarin Pharma, INC. | $53.43 | 2021 | |
| Horizon Therapeutics Plc | $53.25 | 2023 | Tepezza |
| Recordati_rare_diseases_inc. | $51.36 | 2024-2025 | Isturisa, Signifor Lar |
| Nevro Corp. | $46.62 | 2022-2023 | Senza |
| Ascendis Pharma Endocrinology INC | $45.22 | 2025 | Yorvipath |
| Janssen Pharmaceuticals, INC | $42.87 | 2019 | |
| Becton, Dickinson and Company | $41.43 | 2019-2022 | |
| Shire North American Group INC | $40.43 | 2019 | |
| Sequel Med Tech, LLC | $24.95 | 2025 | Twiist |
| Cequr Corporation | $22.04 | 2024 | Cequr Simplicity |
| Zealand Pharma US, INC. | $21.23 | 2022 | |
| Medtronic Minimed, INC. | $20.40 | 2020 | |
| Esperion Therapeutics, INC. | $19.83 | 2022 | |
| Halozyme INC | $17.03 | 2023 | |
| Valeritas, INC. | $15.37 | 2019 | |
| Amphastar Pharmaceuticals, INC. | $14.17 | 2025 | Baqsimi |
| Pfizer INC. | $13.69 | 2024 | |
| Lifescan, INC. | $13.03 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lane Frey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.